InVivo Therapeutics Holdings Corp. (NVIV) today announced the
company will host a Key Opinion Leader (KOL) Event and Company Update in
New York on Thursday, December 3 from 5-7PM ET.
The meeting will feature presentations by two renowned key opinion
leaders: Bob Langer, Sc.D., the David H. Koch Institute Professor at
Massachusetts Institute of Technology and co-founder of InVivo; and Nick
Theodore, M.D., Chief of Spinal Surgery at the Barrow Neurosurgical
Institute and the neurosurgeon who performed the first Neuro-Spinal
Scaffold™ implantation. Dr. Langer will discuss his contributions to
the development of the field of biomaterials and InVivo’s product
candidates that evolved from work performed in his laboratory. Dr.
Theodore will present current state-of-the-art surgical treatment of
spinal cord injury patients and a case study of the first patient in
InVivo’s ongoing Neuro-Spinal Scaffold study. In addition, Mark
Perrin, Chief Executive Officer and Chairman of InVivo, and members of
InVivo’s executive management team will provide several important
company updates.
“We are very pleased to be joined by such accomplished and
well-respected thought leaders for our first company-hosted analyst and
investor presentation. Dr. Langer and Dr. Theodore will share their
unique perspectives on their respective fields and InVivo’s pioneering
work,” Perrin said. “The company has made tremendous progress over the
last year, and we are pleased to be able to have the opportunity to
share these significant accomplishments.”
The event will be broadly accessible via a live webcast through http://lifesci.rampard.com/20151203
that will begin at 5:15PM ET on the day of the event. A replay of the
webcast will be available soon after the event’s conclusion at the same
URL.
In-person attendance is by invitation only with RSVP required.
About the Neuro-Spinal Scaffold™
Following an acute spinal cord injury, the biodegradable Neuro-Spinal
Scaffold is surgically implanted at the epicenter of the wound and
is designed to act as a physical substrate for nerve sprouting.
Appositional healing to spare spinal cord tissue, decreased
post-traumatic cyst formation, and decreased spinal cord tissue pressure
have been demonstrated in preclinical models of spinal cord contusion
injury. The Neuro-Spinal Scaffold, an investigational device, has
received a Humanitarian Use Device (HUD) designation and is currently
being studied in an Investigational Device Exemption (IDE) pilot study
for the treatment of patients with complete (AIS A) traumatic acute
spinal cord injury.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and clinical-stage
biomaterials and biotechnology company with a focus on treatment of
spinal cord injuries. The company was founded in 2005 with proprietary
technology co-invented by Robert Langer, Sc.D., Professor at
Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who
then was at Boston Children’s Hospital and who now is affiliated with
Massachusetts General Hospital. In 2011, the company earned the David S.
Apple Award from the American Spinal Injury Association for its
outstanding contribution to spinal cord injury medicine. In 2015, the
company’s investigational Neuro-Spinal Scaffold received the 2015
Becker’s Healthcare Spine Device Award. The publicly-traded company is
headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.
![](http://cts.businesswire.com/ct/CT?id=bwnews&sty=20151201005938r1&sid=ntxv4&distro=nx&lang=en)
View source version on businesswire.com: http://www.businesswire.com/news/home/20151201005938/en/
Copyright Business Wire 2015